Eli Lilly Asks FDA to Nix EUA for Bamlanivimab Alone

Eli Lilly has asked the FDA to revoke the Emergency Use Authorization for its monoclonal antibody bamlanivimab as a monotherapy for COVID-19 patients, but said the request was not due to any new safety concerns.

Bamlanivimab in combination with another Lilly antibody, etesevimab, has proven to be a more effective treatment, including against variant strains of the SARS-CoV-2 virus that causes COVID-19 infections.

Eli Lilly and the U.S. government have reworked their supply deal to deliver bamlanivimab only in combination with etesevimab.